Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evommune (EVMN) Equity Average (2024 - 2025)

Evommune (EVMN) has disclosed Equity Average for 2 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 108.41% to $11.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.2 million, a 108.41% increase, with the full-year FY2025 number at $30.7 million, changed N/A from a year prior.
  • Equity Average was $11.2 million for Q4 2025 at Evommune, up from -$163.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $11.2 million in Q4 2025 to a low of -$163.7 million in Q3 2025.